Roche Confident But Cautious On Alzheimer's Hopeful
Key Gantenerumab Readout Next Year
Executive Summary
The Swiss major has highlighted two high-risk, high-reward neurodegenerative programs that could be transformative for the treatment of Alzheimer's and Huntington's disease.
You may also be interested in...
Free Access To High-Cost Aducanumab May Incentivize Phase IV Trial Participants
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.
In Moving Tribute, Former Roche CMO Sandra Horning Is Honored As HBA’s Woman Of the Year
Horning describes challenges of moving from tenured professor to industry executive in accepting the award from the Healthcare Businesswomen’s Association. She is recognized for her ‘epic tenacity’ in advancing medicines and commitment to patients. Pfizer’s Rod MacKenzie receives honorable mentor award.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip's worldwide team, in this podcast version of Five Must-Know Things.